Tags

Type your tag names separated by a space and hit enter

[Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease?].
Prog Urol. 2006 Feb; 16(1):52-7.PU

Abstract

The value of intracavernosal corticosteroid infiltration remains controversial or may even be contraindicated in Peyronie's disease, as it is considered to be ineffective and a source of morbidity.

OBJECTIVE

To retrospectively analyse the efficacy and safety of intracavernosal corticosteroid infiltration in a selected population only presenting clinical criteria of the acute phase of Peyronie's disease (pain and/or recent onset < 6 months).

MATERIAL AND METHOD

Intracavernosal corticosteroid infiltration (weekly or twice-weekly) was performed in or around the plaque. Evaluation was based on clinical criteria according to the course of pain, the nodule and curvature and the rates of improvement, resolution, stabilization and deterioration of these criteria were studied.

RESULTS

In a series of 271 patients, 123 presented criteria of the acute phase of Peyronie's disease. Forty five of these patients were treated exclusively by intracavernosal corticosteroid infiltration. The mean age was 52 +/- 8 years. The number of intracavernosal infiltrations was usually less than 10 (n = 40) with less than 8 injections in the majority of patients (n = 36). Follow-up was 6 months. There were no cases of clinical deterioration. The best results were observed on pain, which decreased (13.6%) or totally resolved (61.4%). Curvature was decreased (20.5%), the plaque decreased (25%) or disappeared (9%). When intracavernosal corticosteroid infiltration is ineffective, it appears useless to administer more than 3 injections. No morbidity was observed.

CONCLUSION

In our population, the reputation of inefficacy and morbidity of local corticosteroid therapy appears to be unjustified. There were no cases of deterioration, but, on the contrary, stabilization and especially very marked and rapid efficacy on pain, but a lesser efficacy on curvature and plaque. Local steroid therapy appears justified during the acute phase, as the injection allows corticosteroids to exert their anti-inflammatory action in situ in line with the pathophysiology of the disease. A standardized, multicentre, prospective, randomized, placebo-controlled study could confirm our impressions.

Authors+Show Affiliations

Fédération d'Urologie-Néphrologie, Hôpital Pasteur Nice, France. demey.a@chu-nice.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

16526540

Citation

Demey, Alexis, et al. "[Is Intracavernosal Corticosteroid Infiltration Really Useless in Peyronie's Disease?]." Progres En Urologie : Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie, vol. 16, no. 1, 2006, pp. 52-7.
Demey A, Chevallier D, Bondil P, et al. [Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease?]. Prog Urol. 2006;16(1):52-7.
Demey, A., Chevallier, D., Bondil, P., Toubol, J., & Amiel, J. (2006). [Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease?]. Progres En Urologie : Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie, 16(1), 52-7.
Demey A, et al. [Is Intracavernosal Corticosteroid Infiltration Really Useless in Peyronie's Disease?]. Prog Urol. 2006;16(1):52-7. PubMed PMID: 16526540.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease?]. AU - Demey,Alexis, AU - Chevallier,Daniel, AU - Bondil,Pierre, AU - Toubol,Jacques, AU - Amiel,Jean, PY - 2006/3/11/pubmed PY - 2006/6/6/medline PY - 2006/3/11/entrez SP - 52 EP - 7 JF - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JO - Prog Urol VL - 16 IS - 1 N2 - UNLABELLED: The value of intracavernosal corticosteroid infiltration remains controversial or may even be contraindicated in Peyronie's disease, as it is considered to be ineffective and a source of morbidity. OBJECTIVE: To retrospectively analyse the efficacy and safety of intracavernosal corticosteroid infiltration in a selected population only presenting clinical criteria of the acute phase of Peyronie's disease (pain and/or recent onset < 6 months). MATERIAL AND METHOD: Intracavernosal corticosteroid infiltration (weekly or twice-weekly) was performed in or around the plaque. Evaluation was based on clinical criteria according to the course of pain, the nodule and curvature and the rates of improvement, resolution, stabilization and deterioration of these criteria were studied. RESULTS: In a series of 271 patients, 123 presented criteria of the acute phase of Peyronie's disease. Forty five of these patients were treated exclusively by intracavernosal corticosteroid infiltration. The mean age was 52 +/- 8 years. The number of intracavernosal infiltrations was usually less than 10 (n = 40) with less than 8 injections in the majority of patients (n = 36). Follow-up was 6 months. There were no cases of clinical deterioration. The best results were observed on pain, which decreased (13.6%) or totally resolved (61.4%). Curvature was decreased (20.5%), the plaque decreased (25%) or disappeared (9%). When intracavernosal corticosteroid infiltration is ineffective, it appears useless to administer more than 3 injections. No morbidity was observed. CONCLUSION: In our population, the reputation of inefficacy and morbidity of local corticosteroid therapy appears to be unjustified. There were no cases of deterioration, but, on the contrary, stabilization and especially very marked and rapid efficacy on pain, but a lesser efficacy on curvature and plaque. Local steroid therapy appears justified during the acute phase, as the injection allows corticosteroids to exert their anti-inflammatory action in situ in line with the pathophysiology of the disease. A standardized, multicentre, prospective, randomized, placebo-controlled study could confirm our impressions. SN - 1166-7087 UR - https://wwww.unboundmedicine.com/medline/citation/16526540/[Is_intracavernosal_corticosteroid_infiltration_really_useless_in_Peyronie's_disease]_ L2 - https://www.diseaseinfosearch.org/result/5697 DB - PRIME DP - Unbound Medicine ER -